Overview
AI-first biotech building deep neural networks for molecular property prediction.
Details
Genesis combines its GEMS platform with internal pipeline programs targeting tough-to-drug diseases. Backed by a16z and NVentures.
Genesis Therapeutics
AI-first biotech building deep neural networks for molecular property prediction. Genesis combines its GEMS platform with internal pipeline programs targeting tough-to-drug diseases. Backed by a16z and NVentures.